Ascend Laborato Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ascend Laborato (US): 6 reconciled FDA prescription therapies, $66.7M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$66.7M
2024 Medicare Part D Spend$54.1M
2024 Medicaid Spend$12.7M
California HCAI SB 17 Filings6 WAC filings (max 56.4% 2-yr change)